Acetoacetate and Acetate Metabolism in Patients With Chronic Kidney Failure.(RENO-TEP)
Study Details
Study Description
Brief Summary
The objective of this study is to nake a comparison between 11c-acetate and 11c-acetoacetate kidney uptake in chronic kidney failure patients.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Chronic kidney failure patients will be ask to perform two positron emission tomography scan during the same day. One, with a 11C-Acetate Tracer and the other with 11C-Acetoacetate. The results will allow to determine the difference between the two tracers and will ultimately be compared with precedent results of healthy controls.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Chronic kidney failure No interventions for the purpose of the study. They will simply undergo two PET scans consecutively |
Radiation: PET scan metabolic day
11C-Acetate and 11C-Acetoacetate PET scans
|
Outcome Measures
Primary Outcome Measures
- Mean in kidney acetate uptake [30 minutes]
Kidney acetate uptake measured by pet scan
- Mean in kidney acetoacetate uptake [30 minutes]
Kidney acetoacetate uptake measured by pet scan
- Mean in kidney acetoacetate metabolism [30 minutes]
Kidney acetoacetate metabolism measured by pet scan
- Mean in kidney acetate metabolism [30 minutes]
Kidney acetate metabolism measured by pet scan
Secondary Outcome Measures
- Mean in heart ejection fraction [30 minutes]
Ejection fraction measured by pet scan
Eligibility Criteria
Criteria
Inclusion Criteria:
-
BMI between 18.5 and 40
-
Kidney failure if GFR betweem 30 and 60 mL/min/1.73m2
-
Stable medication for at least 4 weeks
Exclusion Criteria:
-
Receive cytotoxic therapy for primary or secondary kidney disease within 6 months prior to enrollment
-
Organ Transplant History
-
Class IV congestive heart failure (New York Heart Association)
-
Myocardial infarction, unstable angina, stroke or transient ischemic attack within 12 weeks prior to enrollment
-
Coronary revascularization (percutaneous coronary intervention or arterial bypass) or valve repair/replacement within 12 weeks of enrollment or is scheduled to undergo one of these procedures within 4 weeks of enrollment
-
Any condition outside the realm of renal and cardiovascular disease, such as, but not limited to, malignancy, with a life expectancy of less than 2 years in the clinical judgment of the investigator
-
Active malignancy requiring treatment at Visit 1 (except successfully treated basal or squamous cell carcinoma).
-
Hepatic impairment (aspartate transaminase or alanine transaminase >3x upper limit of normal; or total bilirubin >2x upper limit of normal at time of enrollment
-
Pregnancy or lactation
-
Adherence to a ketogenic diet, consumption of ketogenic products or supplements or intermittent fasting or other diet or supplements that may significantly increase ketones in the past two months.
-
Daily alcohol consumption >2 servings per day
-
Participation in other interventional research projects concurrently or participation in other PET research projects in the last year, which exceeds the recommended limits
-
Inability to lie still in supine position;
-
Medical fluid restriction limiting fluid intake for the procedure
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Université de Sherbrooke
- Nestle Health Science
Investigators
- Principal Investigator: Mélanie Godin, MD, Université de Sherbrooke
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2024-5157